Hims to cut 4% of workforce amid ban on weight-loss drug copies
Telehealth platform Hims & Hers will cut about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
You are not logged in so some information on this page has been withheld. To see more, please log in.